Results showed that H182 treatment suppressed Stat3 DNA-binding activity in tumor tissues (Supplementary Fig. S5A, treated T vs. untreated control, C), in parallel with the suppression of the expression of Stat3 downstream genes, including c-Myc, VEGF, and survivin (Supplementary Figs. S5B and T), compared to untreated control tumors. The gene discussed is BIRC5; the disease is neoplasm.